Introduction: Early detection of advanced fibrosis in steatotic liver disease remains a major clinical challenge, particularly in individuals with type 2 diabetes and hazardous alcohol use. This real-world UK study evaluated the role of the Enhanced Liver Fibrosis (ELF) test as a community screening tool to identify patients requiring further assessment with liver stiffness measurement (LSM).
Introduction:
Early detection of advanced fibrosis in steatotic liver disease remains a major clinical challenge, particularly in individuals with type 2 diabetes and hazardous alcohol use. This real-world UK study evaluated the role of the Enhanced Liver Fibrosis (ELF) test as a community screening tool to identify patients requiring further assessment with liver stiffness measurement (LSM).
Why was this study needed?
Current liver disease is often diagnosed at an advanced stage when treatment options are limited. Simple, non-invasive screening strategies are needed to identify high-risk individuals earlier and facilitate timely intervention.
What did the study show?
Clinical Impact:
This study supports the use of the ELF test as an effective first-line, community-based screening tool for patients with diabetes or hazardous alcohol use. However, interpretation should be tailored to the underlying liver disease, and sequential testing with transient elastography may improve diagnostic accuracy.
Take-Home Message:
The ELF test is a practical non-invasive screening tool for identifying advanced liver disease in high-risk populations. When combined with liver stiffness measurement, it can improve early detection of clinically significant fibrosis and support timely referral for specialist care.
Introduction: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can affect virtually any organ. Although glucocorticoids remain the mainstay of treatment, relapse is common after tapering, and long-term steroid toxicity remains a major concern....
Introduction: Hepatitis B virus (HBV) reactivation remains a potentially serious complication of immunosuppressive and anticancer therapies. While current guidelines classify patients into high-, moderate-, and low-risk categories, this editorial discusses new real-world evidence suggesting that...
Introduction: Liver disease is entering a new era. While steatotic liver disease (SLD) is rapidly becoming one of the world's leading non-communicable diseases, progress toward viral hepatitis elimination has slowed. This editorial highlights the urgent...
Introduction: Therapeutic plasma exchange (TPE) is increasingly used in pediatric acute liver failure (ALF), but it artificially lowers bilirubin and INR, making it difficult to determine whether a child is truly improving or requires urgent...
Introduction: For decades, low-to-moderate alcohol consumption has been considered by some to offer potential cardiovascular benefits. This comprehensive U.S. modeling study re-evaluated the lifetime health impact of alcohol consumption using contemporary cause-specific data on alcohol-related...
Introduction: Advances in genetic sequencing have transformed the understanding of cholestatic liver diseases. Conditions once considered exclusive to children are now recognized in adolescents and adults, with genetic variants increasingly explaining unexplained cholestasis, recurrent pruritus,...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.